Subscribe

Core intelligence file · TGTX-01

TG Therapeutics

NASDAQ: TGTX · Neurology / Immunology

Clinaptis stanceCautious
ConvictionMedium
File status
Maintained · valuation re-underwrite
Updated
Sep 25, 2026
Company thesis
Strengthening
Research
0 connected notes
Current read

“The company thesis strengthened in June, but the stock thesis became less attractive as the rerating capitalized a substantial part of the subcutaneous opportunity before Phase 3 validation. At approximately $57.52, the next decision requires a more precise patient and net-revenue build rather than another directional revenue estimate.”

The maintained investment case

The launch thesis is validated and the base U.S. Briumvi peak-sales assumption is now approximately $2.5 billion around FY33.

  1. The stock, however, is no longer priced on the intravenous franchise alone.
  • Second-quarter U.S. Briumvi revenue reached $227.7 million; first-half revenue was $422.5 million and full-year guidance increased to $890–905 million.
  • The guidance midpoint implies approximately 51% growth and $475 million of second-half revenue, consistent with an approximately $1 billion exit-rate objective.
  • The June Phase 1 update made quarterly self-administered Briumvi credible, but did not establish pivotal success, approval, uptake or limited cannibalization.
  • A standalone value near $35 per share can approach $40–45 with better margins and lifecycle assumptions; prices above $50 require meaningful incremental subcutaneous, indication-expansion or strategic value.

Where the market may differ

Subcutaneous Briumvi changes the asset being valued. The remaining disagreement is how much of that expanded opportunity should be capitalized before Phase 3 and before the commercial mix is known.

  • Phase 1 modeled quarterly AUC at a 1.21 geometric mean ratio versus intravenous Briumvi, with the lower 90% confidence bound at 1.15 against a greater-than-0.80 noninferiority threshold.
  • That makes technical Phase 3 success more probable, but also means a headline primary-endpoint win may not support another rerating.
  • The every-three-month arm must show robust trough exposure, sustained B-cell depletion, acceptable injection tolerability and no discordant MRI or clinical signal.
  • Value depends on winning incremental self-administered patients; conversion of existing intravenous patients changes delivery without necessarily expanding total franchise economics.
What matters most
  1. 01

    Convert $890–905 million of 2026 U.S. Briumvi guidance into a defensible patient, persistence and net-revenue-per-patient bridge.

  2. 02

    Establish whether approximately $2.5 billion of U.S. peak sales requires 35,000 or closer to 38,000–40,000 average treated patients.

  3. 03

    Demonstrate clean every-three-month Phase 3 exposure and B-cell depletion, not technical noninferiority alone.

  4. 04

    Separate incremental subcutaneous patients from intravenous cannibalization.

  5. 05

    Preserve operating leverage while funding subcutaneous manufacturing and broader development.